Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1989 1
1990 1
1997 1
1998 2
1999 1
2000 2
2003 1
2004 2
2005 4
2006 7
2007 5
2008 7
2009 9
2010 11
2011 12
2012 16
2013 9
2014 13
2015 22
2016 18
2017 27
2018 24
2019 27
2020 34
2021 47
2022 42
2023 55
2024 48
2025 80
2026 25

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

500 results

Results by year

Filters applied: . Clear all
The following terms were ignored: %, %, %
The following terms were not found in PubMed: 20JY, 5BAuthor
Page 1
Effect of Self-monitoring of Blood Pressure on Blood Pressure Control in Pregnant Individuals With Chronic or Gestational Hypertension: The BUMP 2 Randomized Clinical Trial.
Chappell LC, Tucker KL, Galal U, Yu LM, Campbell H, Rivero-Arias O, Allen J, Band R, Chisholm A, Crawford C, Dougall G, Engonidou L, Franssen M, Green M, Greenfield S, Hinton L, Hodgkinson J, Lavallee L, Leeson P, McCourt C, Mackillop L, Sandall J, Santos M, Tarassenko L, Velardo C, Wilson H, Yardley L, McManus RJ; BUMP 2 Investigators. Chappell LC, et al. JAMA. 2022 May 3;327(17):1666-1678. doi: 10.1001/jama.2022.4726. JAMA. 2022. PMID: 35503345 Free PMC article. Clinical Trial.
Health-related quality of life associated with fruquintinib in patients with metastatic colorectal cancer: Results from the FRESCO-2 study.
Sobrero A, Dasari A, Aquino J, Lonardi S, Garcia-Carbonero R, Elez E, Yoshino T, Yao J, Garcia-Alfonso P, Kocsis J, Gracian AC, Sartore-Bianchi A, Satoh T, Randrian V, Tomasek J, Chong G, Price T, Yu Z, Geiger A, Chen L, Yang Z, Schelman WR, Kania M, Tabernero J, Eng C. Sobrero A, et al. Eur J Cancer. 2025 Mar 11;218:115268. doi: 10.1016/j.ejca.2025.115268. Epub 2025 Jan 29. Eur J Cancer. 2025. PMID: 39952149 Free article. Clinical Trial.
Instruments of EORTC QLQ-C30 and 5-level EQ-5D, and ECOG performance status (PS) were assessed. Changes from baseline scores for QLQ-C30 and EQ-5D were evaluated and minimally important difference thresholds were used to define stable, improved, or deteriorated QoL. …
Instruments of EORTC QLQ-C30 and 5-level EQ-5D, and ECOG performance status (PS) were assessed. Changes from baseline scores for QLQ- …
Prognostic value of patient-reported outcomes in advanced or metastatic melanoma patients treated with immunotherapy: Findings from the CheckMate-067 study.
Schadendorf D, Lord-Bessen J, Ejzykowicz F, Shi L, Yu P, Srinivasan S. Schadendorf D, et al. Eur J Cancer. 2024 Dec;213:115099. doi: 10.1016/j.ejca.2024.115099. Epub 2024 Oct 28. Eur J Cancer. 2024. PMID: 39520835 Free article. Clinical Trial.
METHODS: PRO data assessed using the European Organization of Research for the Treatment of Cancer Core-30 and EQ-5D-3L at baseline and during subsequent visits after treatment initiation were pooled across treatment arms. ...RESULTS: Baseline and CFB scores for most PRO d …
METHODS: PRO data assessed using the European Organization of Research for the Treatment of Cancer Core-30 and EQ-5D-3L at baseline a …
Patient-reported Outcomes in KEYLYNK-010: Pembrolizumab Plus Olaparib Versus Abiraterone or Enzalutamide for Participants with Biomarker-unselected, Previously Treated Metastatic Castration-resistant Prostate Cancer.
Mehra N, Antonarakis ES, Park SH, Goh JC, McDermott R, Sala Gonzalez N, Fong PC, Greil R, De Santis M, Yanez PE, Huang YH, Begbie SD, Rey F, Kramer G, Suzuki H, Saretsky TL, Ghate SR, Cui Y, Hosius C, Yu EY. Mehra N, et al. Eur Urol Oncol. 2025 Aug;8(4):1030-1040. doi: 10.1016/j.euo.2025.04.018. Epub 2025 Jul 19. Eur Urol Oncol. 2025. PMID: 40685311 Free article. Clinical Trial.
PROs were evaluated using the Brief Pain Inventory-Short Form (BPI-SF), Functional Assessment of Cancer Therapy-Prostate Cancer (FACT-P), and EuroQol 5-Dimension 5-Level (EQ-5D-5L) questionnaires. The PRO endpoints included time to pain progression (TTPP) as per BPI-SF and …
PROs were evaluated using the Brief Pain Inventory-Short Form (BPI-SF), Functional Assessment of Cancer Therapy-Prostate Cancer (FACT-P), an …
Participant-reported Outcomes from the CAPELLA Clinical Trial of Lenacapavir-based Regimens in Heavily Treatment-experienced Adults with HIV.
Ramgopal M, Mezzio DJ, Dunn K, Liu SY, Paul D, Rhee MS, Castagna A. Ramgopal M, et al. AIDS Behav. 2025 May;29(5):1553-1561. doi: 10.1007/s10461-025-04625-x. Epub 2025 Mar 10. AIDS Behav. 2025. PMID: 40063206 Free PMC article. Clinical Trial.
We describe participant-reported, health-related quality-of-life (HRQoL) outcomes with lenacapavir among heavily treatment-experienced people with HIV (PWH) from CAPELLA. Scores from EQ-5D-5L index and visual analogue scale (VAS), Short Form 36 (SF-36), HIV-Symptom Index ( …
We describe participant-reported, health-related quality-of-life (HRQoL) outcomes with lenacapavir among heavily treatment-experienced peopl …
Performance of the EQ-5D-5L With Skin Irritation and Self-Confidence Bolt-On Items in Patients With Urticaria.
Feng J, Yin Y, Luo N, Guo J, Wang D, Mao Z, He Z, Lu C, Li S, Yu J. Feng J, et al. Value Health. 2025 Jun;28(6):915-922. doi: 10.1016/j.jval.2025.02.010. Epub 2025 Mar 5. Value Health. 2025. PMID: 40054768
OBJECTIVES: This study aimed to validate the EQ-5D-5L with the addition of skin irritation and self-confidence bolt-on items in Chinese patients with urticaria. ...CONCLUSIONS: The inclusion of 2 bolt-ons in the EQ-5D-5L enhanced its informativity, convergent validi …
OBJECTIVES: This study aimed to validate the EQ-5D-5L with the addition of skin irritation and self-confidence bolt-on items in Chine …
Health-related quality of life in participants with advanced biliary tract cancer from the randomized phase III KEYNOTE-966 study.
Yoo C, Ueno M, Klümpen HJ, Kelley RK, Vogel A, Furuse J, Ren Z, Yau T, Chan SL, Ozaka M, Oh SC, Gu S, Park JO, Valle JW, Edeline J, Kim JG, Kamble S, Norquist JM, Yu L, Malhotra U, Finn RS. Yoo C, et al. J Hepatol. 2025 Sep;83(3):692-700. doi: 10.1016/j.jhep.2025.03.019. Epub 2025 Mar 27. J Hepatol. 2025. PMID: 40154623 Free article. Clinical Trial.
METHODS: HRQoL was assessed using the EORTC Core Quality of Life Questionnaire (QLQ-C30), EORTC QLQ-BIL21, and EQ-5D-5L questionnaires. Data from the latest time point with 60% completion and 80% compliance (week 18) were compared to baseline. Least squares means for cha …
METHODS: HRQoL was assessed using the EORTC Core Quality of Life Questionnaire (QLQ-C30), EORTC QLQ-BIL21, and EQ-5D-5L questionnaire …
Community-Based Peer Support for Diabetes Management: 24-Month Changes Relative to Comparison Communities.
Liu Y, Cai C, Tian J, Shen L, Tang PY, Coufal MM, Chen H, Evans MS, Qian Y, Yu W, Wu X, Wu X, Fisher EB, Jia W. Liu Y, et al. Diabetes Care. 2025 May 1;48(5):807-815. doi: 10.2337/dc24-2748. Diabetes Care. 2025. PMID: 40163517 Free PMC article.
The primary outcome was HbA1c; secondary outcomes included BMI, fasting plasma glucose (FPG), systolic and diastolic blood pressure, LDL cholesterol (LDL-C), depressive symptoms (PHQ-8), diabetes distress, and general quality of life (EQ-5D). RESULTS: The analyses included …
The primary outcome was HbA1c; secondary outcomes included BMI, fasting plasma glucose (FPG), systolic and diastolic blood pressure, LDL cho …
DAHOS Study: Efficacy of dapagliflozin in treating heart failure with reduced ejection fraction and obstructive sleep apnea syndrome - A 3-month, multicenter, randomized controlled clinical trial.
Xie L, Li S, Yu X, Wei Q, Yu F, Tong J. Xie L, et al. Eur J Clin Pharmacol. 2024 May;80(5):771-780. doi: 10.1007/s00228-024-03643-3. Epub 2024 Feb 22. Eur J Clin Pharmacol. 2024. PMID: 38386021 Clinical Trial.
In the experimental group, BMI was significantly reduced, and there were improvements in ESS score, MLHFQ score, and EQ-5D-3L score, as well as significant reductions in CRP and IL-6 levels, while the CRP and IL-6 levels were not improved in the control group. ...
In the experimental group, BMI was significantly reduced, and there were improvements in ESS score, MLHFQ score, and EQ-5D-3L score, …
Mirikizumab Improves Quality of Life and Work Productivity in Patients with Moderately to Severely Active Crohn's Disease: Results from the Phase 3 VIVID-1 Study.
Lee SD, Vermeire S, Ungaro R, Vadhariya A, Durand F, Morris N, Yu G, Fisher DA, Traxler K, Long M. Lee SD, et al. Am J Gastroenterol. 2025 Mar 13;120(8):1809-1819. doi: 10.14309/ajg.0000000000003410. Am J Gastroenterol. 2025. PMID: 40079470 Free PMC article. Clinical Trial.
The effect of mirikizumab on HRQoL was assessed at weeks 12 and 52 using the Inflammatory Bowel Disease Questionnaire (IBDQ), Short Form-36 Health Survey (SF-36), EQ-5D-5L visual analog scale, and Work Productivity and Activity Impairment: CD measures. ...RESULTS: Greater …
The effect of mirikizumab on HRQoL was assessed at weeks 12 and 52 using the Inflammatory Bowel Disease Questionnaire (IBDQ), Short Form-36 …
500 results